Q-omics provides the consensus-scored TMEM179 profile across patient tissues and cancer cell-line models. TMEM179 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM179 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TMEM179 RNA expression shows 14,342 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, COAD, and TGCT as cancer lineages where TMEM179 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM179 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM179 survival associations across molecular data types. TMEM179 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM179 RNA expression–survival associations across cancer types. High TMEM179 expression shows unfavorable associations in ESCA, KIRP and HNSC, but favorable associations in ACC, LGG and THCA. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM179 RNA expression.
This table summarizes TMEM179 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM179. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM179 shows lower tumor expression in COAD, KICH, READ and STAD and higher tumor expression in KIRC and KIRP. The COAD box plot shows higher TMEM179 RNA expression in normal versus tumor tissue (log2 FC = −0.803, t-test p < 0.001).
This table shows molecular features associated with TMEM179 in patient tissues and cancer cell lines. In patient samples, TMEM179 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM179 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_SCLC.
